CFTR and cystic fibrosis: Significant improvements in lung function have been observed in patients on CFTR modulators, the most recent being elexacaftor/ivacaftor/tezacaftor (Heijerman et al., 2019; Keating et al., 2018; Middleton et al., 2019), a triple combination therapy that rescues the trafficking of the most common CF‐causing mutant, F508del CFTR, and potentiates chloride secretion.